The Philadelphia Business Journal reported on July 30th that Plymouth Meeting-based Harmony Biosciences is planning to offer an initial public stock offering.

From the Philadelphia Business Journal:

Harmony Biosciences has filed plans to raise $100 million through an initial public stock offering.

The IPO, if completed, would be the fourth by a local life sciences company this year.

Based in Plymouth Meeting, Harmony markets the drug Wakix for patients with the sleep disorder narcolepsy.

You can read the full article here.